Pharma & Biotech Global Week in Review 11 July 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Fortamet (Metformin) – US: CAFC again vacates preliminary injunction in Sciele Pharma v Lupin (Orange Book Blog) (Patent Docs) (Patently-O)

USPTO issues Prometheus examination guidelines (Pharma Patents) (Patent Docs) (Director’s Forum)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

“Landmark” global commission on HIV and law report tough on IP system (IP Watch)

Australia: APO: Celgene tries – and fails – again with drug safety business model (Patentology)

Canada: The Patented Medicines Review Board and its proposed new regulations (IP Osgoode)

EU: How farmers should pay up for infringing protected plant variety rights – summary of Case C‑509/10 Geistbeck v Saatgut-Treuhandverwaltungs GmbH (IPKat)

Italy: Antitrust and SPCs in Italy (The SPC Blog)

Turkey: Who is an average sonsumer of healthcare products in Turkey? NOVARTIS v NOVITAS (Class 46)

UK: Medeva – appeal lodged against Court or Appeal decision (The SPC Blog)

US: Seed patents: How innovatyion may get lost in the grain elevator: Bowman v Monsanto (BIOtechNOW)

US: Affordable Care Act survives Supreme Court review largely unscathed, clearing way for biosimilars (Patent Docs)

US: A look at Abbott’s Citizen Petition against the Biologics Price Competition And Innovation Act (Pharma Patents)

USPTO issues Prometheus examination guidelines (Pharma Patents) (Patent Docs) (Director’s Forum)

US: Supreme Court to regulatory agencies: Due process requires “fair notice” of agency interpretations: Christopher v Smithkline Beecham and FCC v Fox Television Stations (FDA Law Blog)

US: Eli Lilly & Co. file amicus brief in AMP v. USPTO (Myriad ) (Patent Docs)

US: IPO amicus brief argues for patent eligibility of Myriad’s isolated DNA claims and method claim 20: AMP v. USPTO (Myriad ) (Patent Docs)

U.S. Government: Mayo decision supports prior argument that isolated genomic DNA is not patent eligible: AMP v. USPTO (Myriad ) (Patent Docs)

 

Products

Acedote (N-acetylcysteine) – US: Cumberland Pharmaceuticals files patent infringement suit against Sagent Agila in reponse to Para IV challenge (Patent Docs)

Epiduo (Adapalene, Benzoyl peroxide) – US: Galderma files patent infringement suit against Actavis Mid Atlantic in response to Para IV certification (Patent Docs)

Focalin XR (Dexmethylphenidate) – US: Alkermes files patent infringement suit against Intellipharmaceutics in response to Para IV challenge (Patent Docs)

Focalin XR (Dexmethylphenidate) – US: Celegene files patent infringement suit against Intellipharmaceutics in response to Para IV challenge (Patent Docs)

Fortamet (Metformin) – US: CAFC again vacates preliminary injunction in Sciele Pharma v Lupin (Orange Book Blog) (Patent Docs) (Patently-O)

Lidoderm (Lidocaine) – US: Endo files patent infringement suit against Noven in response to Para IV challenge (Patent Docs)

Lipidil EZ (Fenofibrate) – Canada: Federal Court: Absence of evidence of direct specific infringement sinks prohibition applications made by Fournier against Sandoz (Beeser Ramamoorthy) (Beeser Ramamoorthy)

Makena (Hydroxyprogesterone) – US: FDA sued for abrogating Makena orphan drug exclusivity; suit alleges that FDA is turning a blind eye to compounded 17P and bowing to political pressure: K-V Pharmaceutical, Ther-RX v FDA (FDA Law Blog)

Nexium (Esomeprazole) – Netherlands: District Court of The Hague rejects Ranbaxy’s change of claim in declaration on non-infringement case against AstraZeneca (EPLAW)

Nexium (Esomeprazole) – US: FDA petitioned on 180-day exclusivity forfeiture for tentative approvals that occur on the 30-month ANDA submission anniversary date (FDA Law Blog)

OxyContin (Oxycodone) – US: Purdue files patent infringement complaints against Sandoz and Teva in response to Para IV certification filing (Patent Docs)

Pristique (Desvenlafaxine) – US: Pfizer, Wyeth file patent infringement suit against Roxane in response to Para IV challenge (Patent Docs)

Pristique (Desvenlafaxine) – US: Pfizer, Wyeth file patent infringement suits against Mylan, Anchen, Watson, Sandoz, Zydus, Breckenridge, Teva and others in response to Para IV challenges (Patent Docs)

Reclast (Zoledronic) – US: Novartis files patent infringement complaint against Wockhardt in response to Para IV certifications (Patent Docs)

Seroquel (Quetiapine) – US: DC District Court rules for FDA in generic Seroquel exclusivity case; grants motion for summary judgment: AstraZeneca v FDA (FDA Law Blog)

Xibrom (Bromfenac) – US: Judge supports FDA decision approving generic Bromfenac: ISTA v FDA  (FDA Law Blog)

Yasmin (Ethinylestradiol, Drospirenone) – Netherlands: Preliminary injunction awarded in Bayer v Sandoz (EPLAW)

Zemplar (Paricalcitol) – US: Abbott files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: